Men with prostate cancer can safely exercise, benefiting from reduced treatment side effects, improved mental health, and ...

May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

Prostate cancer incidence in the US shows a concerning rise, particularly in advanced stages. While early prostate cancer ...

As this year's awareness month comes to a close, Taub informs patients of the most common warning signs and symptoms of the disease, as well as explains the standard methods for diagnosing prostate ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Hormone-suppressing drugs, increasingly used to treat prostate cancer, make men so prone to broken bones that the risks of the treatment may outweigh the benefits in those whose cancer was caught ...

Please provide your email address to receive an email when new articles are posted on . Men without bone pain at diagnosis achieved longer PFS and OS. Bone pain at diagnosis should be a factor for ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...